A recent phase II clinical trial (NCT05077709) shows that applying a cancer vaccine (IO102-IO103) targeting IDO and PD-L1 along with an anti-PD-1 antibody (keytruda) has promising clinical effects on patients with metastatic NSCLC, with a disease control rate of more than 80% [252]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.